Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – A multicenter single arm open label phase II trial (SAKK 15/19)
Adding consolidative TRT after chemotherapy plus durvalumab in ES-SCLC didn't meet the primary endpoint of the expected 12-month PFR. No additional severe toxicities from TRT were observed. Ongoing larger Phase III trials, including RAPTOR (LNRG LU007), will further define TRT's role in this setting.
Authors
- C Picardi (ORCID: https://orcid.org/0009-0005-3298-3958)
- Nicolas Mach (ORCID: https://orcid.org/0000-0001-8944-1088)
- David König (ORCID: https://orcid.org/0000-0003-3559-6855)
- Markus Joerger (ORCID: https://orcid.org/0000-0001-6602-6287)
- Eugenio Fernández (ORCID: https://orcid.org/0000-0002-3813-1888)
- Hansjörg Vees
- Martina Imbimbo (ORCID: https://orcid.org/0000-0003-2521-7540)
- Annalea Patzen
- Alfredo Addeo (ORCID: https://orcid.org/0000-0003-0988-0828)
- Michael Mark
- Patrizia Froesch (ORCID: https://orcid.org/0000-0002-8140-1249)
- Martin Früh
- Daniel Dietrich
Institutions
- Kantonsspital St. Gallen (CH)
- University Hospital of Basel (CH)
- Ente Ospedaliero Cantonale (CH)
- Klinik Hirslanden (CH)
- University Hospital of Geneva (CH)
- Swiss Group For Clinical Cancer Research (CH)
- Kantonsspital Graubünden (CH)
- Università della Svizzera italiana (CH)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1016/j.ejca.2025.116138
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung